Boehringer begins patient enrolment in nintedanib trial to treat SSc and SSc-ILD

Germany-based Boehringer Ingelheim has begun enrolling patients in a global Phase III trial (Senscis) of nintedanib, a potential treatment for systemic sclerosis (SSc).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news